Which feature best distinguishes calcineurin inhibitors (cyclosporine and tacrolimus) from mTOR inhibitors (sirolimus and everolimus) in terms of their immunosuppressive mechanism?

Explanation

## Mechanism-Based Distinction Between Calcineurin Inhibitors and mTOR Inhibitors ### The Core Question The stem asks what **best distinguishes** calcineurin inhibitors (CNI) from mTOR inhibitors (mTORi). The correct answer must be a feature unique to one class and not shared by the other. ### Calcineurin Inhibitors (CNI): Cyclosporine & Tacrolimus **Key Point:** CNI bind to cytoplasmic immunophilins (cyclosporine → cyclophilin; tacrolimus → FKBP12). The drug–immunophilin complex then inhibits **calcineurin**, a phosphatase that normally dephosphorylates NFAT. By blocking NFAT dephosphorylation, CNI prevent NFAT nuclear translocation and suppress **IL-2 gene transcription**. This arrests T cells at the **G0/G1 phase** — before IL-2 is even produced. ### mTOR Inhibitors (mTORi): Sirolimus & Everolimus **Key Point:** mTORi also bind **FKBP12**, but the resulting complex inhibits **mTOR kinase** (not calcineurin). mTOR normally phosphorylates **S6 kinase (S6K1)** and **4E-BP1**, driving ribosomal protein synthesis and cell-cycle progression. By blocking these substrates, mTORi prevent T cell proliferation at the **G1/S phase** — *after* IL-2 has been produced and has bound its receptor. *(KD Tripathi, Essentials of Medical Pharmacology, 8th ed.)* ### Comparative Table | Feature | Calcineurin Inhibitors | mTOR Inhibitors | |---------|------------------------|-----------------| | **Immunophilin partner** | Cyclophilin (CsA) / FKBP12 (Tac) | FKBP12 | | **Molecular target** | Calcineurin phosphatase | mTOR kinase | | **Downstream block** | NFAT dephosphorylation → ↓ IL-2 production | S6K & 4E-BP1 phosphorylation → ↓ protein synthesis | | **Cell cycle arrest** | G0/G1 | G1/S | | **Effect on IL-2** | Prevents production | Blocks response (IL-2 still produced) | | **Nephrotoxicity** | Yes | No | ### Why Option D is Correct **Option D — "Prevention of T cell proliferation by blocking S6 kinase and 4E-BP1 phosphorylation"** — describes the mechanism **unique to mTOR inhibitors**. This downstream block of protein synthesis is the defining mechanistic distinction from CNI, which act upstream at IL-2 production. ### Why the Other Options Are Wrong - **Option A** (Inhibition of IL-2 production via NFAT dephosphorylation) describes the CNI mechanism, not the distinguishing feature of mTORi. - **Option B** (Selective CD4+ sparing of CD8+) is pharmacologically incorrect — neither CNI nor mTORi selectively spare CD8+ T cells; both suppress T cells non-selectively. - **Option C** (Direct binding to FKBP12) is **shared** by tacrolimus AND sirolimus/everolimus; it cannot distinguish the two classes. **High-Yield:** The best discriminator is the downstream target: CNI block IL-2 *production* (upstream, NFAT-dependent), while mTORi block IL-2 *signalling response* (downstream, via S6K and 4E-BP1). Option D correctly identifies the mTORi-specific mechanism. **Clinical Pearl:** In renal transplantation, CNI are preferred for induction due to superior early immunosuppression, while mTORi are used in maintenance regimens to reduce nephrotoxicity and provide anti-proliferative effects on vascular smooth muscle cells, reducing chronic allograft vasculopathy.